Linnea SA ’s Post

Excited to announce that our research, "A Prospective Observational Study on Determining the Utilization of Restricted Antibiotics Using Defined Daily Dose Calculations in A Quaternary Care Hospital," has been published in the International Journal of Pharmacy and Pharmaceutical Research (IJPPR), Volume 30, Issue 8, August 2024! 📖 Our study explores the usage patterns of restricted antibiotics across different departments and clinical conditions in the hospital setting, highlighting the importance of adherence to antimicrobial stewardship policies to prevent the rise of antibiotic resistance. Among the findings, Meropenem emerged as the most frequently prescribed antibiotic in our hospital setting. This work is the result of dedicated collaboration, and I'm grateful to have worked alongside co-authors Bala Krishnan P., John Felix S.N., Deepak Hari S.S., Vigneswaran R., Dr. Vishnu T., and Dr. Guru Prasad Mohanta. You can find the full article in IJPPR https://lnkd.in/gDmszirT #pharmacyresearch #antibioticresistance #antimicrobialstewardship #healthcare #scientificpublication #hospitalpharmacy #quaternarycare

📌 Amneal resubmits the DHE autoinjector application and receives FDA's approval for its first generic injectable GLP-1 agonist, Exenatide. 📊 Amneal posted its Q3 2024 financial results on Nov 8, 2024. 🗓️ Amneal announced plans to release its Q3 2024 results on Nov 8, 2024. 💊 In collaboration with Metsera, Amneal will develop and supply new treatments for obesity and metabolic diseases globally. 🧪 Amneal introduced Crexont®, an extended-release capsule for treating Parkinson's disease. #DataPorium #Amneal #HealthcareInnovation #Pharmaceuticals #FDAApproval At DataPorium, we track the financial performance, product sales, market share, and social network analysis. We also track the trends of nearly 1,000 products every quarter. 🚀 Want to see more? Head over to https://lnkd.in/duDAwekv and explore! 🔗 Visit our LinkedIn page https://lnkd.in/gJ2iKqKw today for exclusive updates—completely free!

🔬 Acurx Unveils New Findings at IDWeek! 🌟 Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) presented promising bile acid and microbiome analyses from their Phase 2b trial of Ibezapolstat in CDI patients at the IDWeek Scientific Conference. These insights mark an exciting step forward in the fight against Clostridioides difficile infections! READ HERE👇🏻👇🏻👇🏻 https://lnkd.in/dXD92AiK #acurxpharmaceuticals #wellness #health #healthcare #cure #medicine #pharmacy #science #businessupdate #businessnews #business #news #newtothestreet

NPPA Revised the Ceiling Prices of 8 Essential Drugs by 50% The National Pharmaceutical Pricing Authority (NPPA) revised the ceiling prices of 8 essential drugs, including Metoprolol, Glimepiride, Amlodipine, and Salbutamol, to ensure both affordability and availability under public health programs. These changes are aimed at balancing patient access to affordable medicines while maintaining drug supply in the market. The price revision affects critical drugs used in treating cardiovascular diseases, diabetes, and respiratory conditions. [Hospital, News of Hospital Industry, Latest in Hospital Industry, Hospital Industry News, Healthcare News, NABH] Social Links: Whatsapp Channel: https://lnkd.in/gwPpryHa Instagram: https://lnkd.in/gWfE63R7 Twitter: https://lnkd.in/gT6Ge-tA Facebook: https://lnkd.in/gDaEPViV Youtube: https://lnkd.in/gd-R4pfr Telegram Channel: https://lnkd.in/garUNS5C

Drugs Flagged as Spurious in November 2024 The Central Drugs Standard Control Organisation (CDSCO) has identified two drugs as spurious and flagged them in their November 2024 update. These drugs are: Taxim-O 200 (Alkem Laboratories) – Antibiotic Pan D (Alkem Laboratories) – Antacid In addition, CDSCO has also listed 111 drugs as failing to meet quality standards. It's crucial for healthcare professionals, pharmacists, and consumers to stay informed and ensure the safety and efficacy of the medicines being prescribed or consumed. CDSCO typically releases such updates monthly to keep the public and healthcare community informed about potentially harmful or substandard medications in the market. For the full list and further updates, visit the official CDSCO website: https://lnkd.in/gNcehJAC #Pharma #Healthcare #DrugSafety #PharmaceuticalIndustry #Regulations #QualityControl #SpuriousDrugs

For over 50 years, #heparin has been a cornerstone in thrombosis treatment, with ongoing research into its potential in diseases like COPD and malaria. Heparinoids, offering versatility in administration, are now making their mark in wound healing and inflammatory diseases. Joan Bassa Camps, our Human Health Business Unit Director, talks to Pharmaceutical Technology Europe about the history of #heparin, its uses in pharmaceuticals, and what heparinoids have to offer the industry. ☝ Want to know more? Enter here: ⤵ https://lnkd.in/dnrJFU5i #HumanHealth #WeAreAllOne #CPHI2024 #HealthForAll #Heparinoids

Antimicrobial resistance (#AMR) occurs when superbugs are no longer contained by antibiotics & other treatments. What does this mean? An estimated 39 million people will die from AMR between 2025-2050, AMR makes it harder to combat diseases like tuberculosis, and routine surgeries and medical procedures are riskier as the effectiveness of antibiotics declines. Watch below to see what concerns leading experts most about this growing health issue & stay tuned to hear from Management Sciences for Health & others later this week about what we can do to fight AMR.

🚀 Innoviva Secures Exclusive U.S. Rights for Zevtera Antibiotic! 🦠 Innoviva Specialty Therapeutics has made a significant leap in the critical care market by partnering with Basilea Pharmaceutica to bring Zevtera (ceftobiprole) to the U.S. 🌟 🔑 Key Highlights: - FDA Approval: Zevtera is the only cephalosporin antibiotic approved for treating MRSA bloodstream infections and endocarditis in adults, enhancing Innoviva's portfolio of differentiated treatments. - Strategic Investment: An upfront payment of $4 million, along with tiered royalties based on sales performance, reflects Innoviva's confidence in Zevtera’s market potential. - Market Launch: With a planned launch in mid-2025, Innoviva is poised to address critical healthcare needs and improve patient outcomes against drug-resistant infections. This strategic move not only diversifies Innoviva’s therapeutic offerings but also reinforces its commitment to combating serious infections. 👉 Click on the link for more details! #Antibiotics #CriticalCare #FDA #InnovativeHealthcare #MRSA #Partnership #Pharma #PharmaceuticalCompanies #Pharmaceuticals #RegulatoryAgencies #MarketAccess #MarketAccessToday

Gan & Lee Pharmaceuticals (SHSE: 603087) has successfully administered the first dose of its biosimilar drug, GLR1023 injection (proposed as a biosimilar to Secukinumab), in a Phase 1 clinical study targeting moderate to severe plaque psoriasis in healthy participants in China. This randomized, blinded, single-dose, positive control trial aims to evaluate the pharmacokinetic parameters, immunogenicity, and safety of GLR1023 compared to the reference product, Secukinumab, in healthy adult males. Psoriasis is a chronic, immune-mediated, and recurrent skin disease that can last for decades and affect the physical and mental health of patients. Following the data released by the National Psoriasis Foundation (NPF), it is estimated that 125 million people worldwide have psoriasis. The global prevalence of psoriasis is 2 to 3 percent of the total population and can develop at any age in both males and females. According to data, the global sales of Secukinumab reached $4.788 billion in 2022. #Biosimilars #ClinicalTrials #Psoriasis #Innovation #Healthcare #Pharmaceuticals #QimingPortfolio #QimingHealthcare

💊🔬 Acurx: Pioneering the Future of Antibiotics 🌟 Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) is a clinical-stage biopharma company on a mission to combat life-threatening bacterial infections with a groundbreaking new class of antibiotics. As antibiotic resistance rises, Acurx is leading the charge in developing innovative solutions to protect global health. 🧫⚕️ Click the link for the full video👇🏻👇🏻👇🏻 https://lnkd.in/eRfYz7zB #acurxpharmaceuticals #wellness #health #healthcare #cure #medicine #pharmacy #science #businessupdate #businessnews #business #news #newtothestreet